Literature DB >> 33249320

Detraining effects after 18 months of high intensity resistance training on osteosarcopenia in older men-Six-month follow-up of the randomized controlled Franconian Osteopenia and Sarcopenia Trial (FrOST).

Wolfgang Kemmler1, Matthias Kohl2, Michael Fröhlich3, Daniel Schoene4, Simon von Stengel5.   

Abstract

PURPOSE: Detraining after dedicated exercise programs might be a frequent situation in older people's exercise patterns. The aim of the present study was thus to determine the effects of 6 months of detraining after 18 months of high intensity resistance exercise (HIT-RT) on musculoskeletal outcomes in older men with sarcopenia.
METHODS: Community-dwelling men aged 72 years and older with osteosarcopenia (n = 43) were randomly assigned to an 18-month HIT-RT (EG: n = 21) or a non-training control group (CG, n = 22). After the intervention, participants of the EG stopped HIT-RT for 6 months, but continued their habitual physical activity. Study outcomes were skeletal muscle mass index, bone mineral density (BMD) at the lumbar-spine and total-hip, maximum hip/leg-extensor strength, handgrip strength and gait velocity. We applied an intention-to-treat analysis with multiple imputation.
RESULTS: Changes in the HIT-RT were much more pronounced during the detraining period compared with the CG, although this effect was only significant for skeletal muscle mass index and hip-/leg-extensor strength (p = .002 and p = .013), but not for lumbar-spine BMD (p = .068), total-hip BMD (p = .069), handgrip strength (p = .066) or gait velocity (p = .067). Apart from total-hip BMD (p = .055), handgrip strength (p = .069) and gait velocity (p = .881) values of the HIT-RT group decreased significantly during detraining. However, after 24 months, overall effects (p < .001) were still observed for skeletal muscle mass index and hip-/leg-extensor strength.
CONCLUSION: Although unable to state from which point in time relevant detraining effects emerge, we conclude that health care providers should focus on continuous rather than intermitted exercise programs for older people. Clinical trial number: clinicalTrials.gov: NCT03453463; NCT04444661.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone mineral density; Detraining; Older men; Resistance exercise; Sarcopenia

Mesh:

Year:  2020        PMID: 33249320     DOI: 10.1016/j.bone.2020.115772

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Detraining Effects on Musculoskeletal Parameters in Early Postmenopausal Osteopenic Women: 3-Month Follow-Up of the Randomized Controlled ACTLIFE Study.

Authors:  Wolfgang Kemmler; Michael Hettchen; Matthias Kohl; Marie Murphy; Laura Bragonzoni; Mikko Julin; Tapani Risto; Simon von Stengel
Journal:  Calcif Tissue Int       Date:  2021-03-12       Impact factor: 4.333

2.  Changes in Body Composition and Cardiometabolic Health After Detraining in Older Men with Osteosarcopenia: 6-Month Follow-Up of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST) Study.

Authors:  Wolfgang Kemmler; Daniel Schoene; Matthias Kohl; Simon von Stengel
Journal:  Clin Interv Aging       Date:  2021-04-06       Impact factor: 4.458

3.  Physical Activity at Growth Induces Bone Mass Benefits Into Adulthood - A Fifteen-Year Prospective Controlled Study.

Authors:  Björn E Rosengren; Jakob Rempe; Lars Jehpsson; Magnus Dencker; Magnus K Karlsson
Journal:  JBMR Plus       Date:  2021-11-26

4.  Detraining Effects on Muscle Quality in Older Men with Osteosarcopenia. Follow-Up of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST).

Authors:  Mansour Ghasemikaram; Klaus Engelke; Matthias Kohl; Simon von Stengel; Wolfgang Kemmler
Journal:  Nutrients       Date:  2021-05-01       Impact factor: 5.717

Review 5.  Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review.

Authors:  Rashmi Supriya; Kumar Purnendu Singh; Yang Gao; Yaodong Gu; Julien S Baker
Journal:  Biology (Basel)       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.